Rafael López‐López

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Maria Victoria García‐Ortiz · 2 shared papers, 2024–2025 · strength 0.50
   • Paper Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance. DOI 10.1016/j.critrevonc.2025.104807↗
   • Paper Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. DOI 10.1016/j.ctrv.2024.102719↗
2. Marta Toledano‐Fonseca · 2 shared papers, 2024–2025 · strength 0.50
   • Paper Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance. DOI 10.1016/j.critrevonc.2025.104807↗
   • Paper Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. DOI 10.1016/j.ctrv.2024.102719↗
3. Elena Brozos-Vázquez · 2 shared papers, 2024–2025 · strength 0.50
   • Paper Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance. DOI 10.1016/j.critrevonc.2025.104807↗
   • Paper Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. DOI 10.1016/j.ctrv.2024.102719↗
4. Antonio Rodríguez‐Ariza · 2 shared papers, 2024–2025 · strength 0.50
   • Paper Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance. DOI 10.1016/j.critrevonc.2025.104807↗
   • Paper Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. DOI 10.1016/j.ctrv.2024.102719↗
5. Enrique Aranda · 2 shared papers, 2024–2025 · strength 0.50
   • Paper Unveilling the potential of liquid biopsy in pancreatic cancer for molecular diagnosis and treatment guidance. DOI 10.1016/j.critrevonc.2025.104807↗
   • Paper Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. DOI 10.1016/j.ctrv.2024.102719↗
6. Fernando Rivera · 2 shared papers, 2015–2019 · strength 0.13
   • Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
   • Paper Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in meta… DOI 10.1586/14737167.2015.1047349↗
7. Teresa Mercade Macarulla · 2 shared papers, 2015–2019 · strength 0.13
   • Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
   • Paper Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in meta… DOI 10.1586/14737167.2015.1047349↗
8. Andrés Jesús Muñoz Martín · 1 shared paper, 2019 · strength 0.08
   • Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
9. Joaquina Martínez-Galán · 1 shared paper, 2019 · strength 0.08
   • Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
10. Adelaida La Casta · 1 shared paper, 2019 · strength 0.08
    • Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
11. Ruth Vera · 1 shared paper, 2019 · strength 0.08
    • Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
12. Roberto Pazo-Cid · 1 shared paper, 2019 · strength 0.08
    • Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
13. Manuel M. Hidalgo · 1 shared paper, 2019 · strength 0.08
    • Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
14. Carmen Guillén‐Ponce · 1 shared paper, 2019 · strength 0.08
    • Paper Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemci… DOI 10.1200/jco.18.00089↗
15. Ferran Pérez-Alcántara · 1 shared paper, 2015 · strength 0.05
    • Paper Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in meta… DOI 10.1586/14737167.2015.1047349↗
16. Alfredo Carrato · 1 shared paper, 2015 · strength 0.05
    • Paper Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in meta… DOI 10.1586/14737167.2015.1047349↗
17. Sonia Candamio Folgar · 1 shared paper, 2013 · strength 0.03
    • Paper Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study). PMID 23393373↗
18. Mónica Jorge Fernández · 1 shared paper, 2013 · strength 0.03
    • Paper Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study). PMID 23393373↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.